{"id":2800,"date":"2021-01-01T12:01:00","date_gmt":"2021-01-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/der-neutralisierende-monoklonale-antikoerper-ly-cov555-zur-behandlung-von-patienten-mit-covid-19"},"modified":"2021-01-01T12:01:00","modified_gmt":"2021-01-01T11:01:00","slug":"der-neutralisierende-monoklonale-antikoerper-ly-cov555-zur-behandlung-von-patienten-mit-covid-19","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2021\/der-neutralisierende-monoklonale-antikoerper-ly-cov555-zur-behandlung-von-patienten-mit-covid-19","title":{"rendered":"Der neutralisierende monoklonale Antik\u00f6rper LY-CoV555 zur Behandlung von Patienten mit COVID-19"},"content":{"rendered":"<p>Zur Behandlung von SARS-CoV-2-infizierten Patienten werden auch Antik\u00f6rper gegen das Virus entwickelt. Einer von ihnen, LY-CoV555 entspricht dem Muster von Antik\u00f6rpern eines Patienten, der COVID-19 \u00fcberlebte. Er ist auch unter LY3819253 oder Bamlanivimab bekannt (AbCellera, Eli Lilly und National Institute of Allergy and Infectious Diseases) und von der FDA zugelassen. LY-CoV555 bindet mit hoher Affinit\u00e4t [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zur Behandlung von SARS-CoV-2-infizierten Patienten werden auch Antik\u00f6rper gegen das Virus entwickelt. Einer von ihnen, LY-CoV555 entspricht dem Muster von Antik\u00f6rpern eines Patienten, der COVID-19 \u00fcberlebte. Er ist auch unter LY3819253 oder Bamlanivimab bekannt (AbCellera, Eli Lilly und National Institute of Allergy and Infectious Diseases) und von der FDA zugelassen. LY-CoV555 bindet mit hoher Affinit\u00e4t [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5450,5451,5340,5339,5453,5452,5338],"class_list":["post-2800","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-activ-3-tico-ly-cov555-studie","tag-bamlanivimab","tag-coronavirus","tag-covid-19","tag-ly-cov555","tag-ly3819253","tag-sars-cov-2"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2800"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2800\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}